Kilitch Drugs (India) rights issue

As per the ratio of 2:23, the issue price of the shares under Kilitch Drugs (India)’s right issue on the record date of 15-07-2025 is 357 per equity share.

You can apply for Kilitch Drugs (India)’s right issue online if your bank supports the Applications Supported by Blocked Amount (ASBA) process.
For offline, Kilitch Drugs (India)’s Registrar and Transfer Agent (RTA) sends the Composite Application Form (CAF) to each shareholder entitled to receive the Rights Issue. Fill out and submit the form to a Self-Certified Syndicate Bank (SCSB) branch (WEB).
Alternatively, you can use your bank account sharing the same PAN number as your Choice Demat account to apply for Kilitch Drugs (India)'s rights issue.

The record date for Kilitch Drugs (India) rights issue 2025 is 15-07-2025

The last day to apply for Kilitch Drugs (India)’s rights issue is 15-07-2025. This date typically falls within a period of 15 to 30 days, from the Rights Issue Opening Date, which in this case is 02-07-2025.

Yes, subscribing to Kilitch Drugs (India)’s right issue has certain tax implications:

1. Subscription: There’s no immediate tax liability. The cost of acquisition is the subscription price plus transaction charges.
2. Capital Gains on Sale:
   • Short-Term: Gains from shares sold within 12 months are taxed at 20%.
   • Long-Term: Gains from shares held over 12 months are taxed at 12.5% (exceeding ₹1.25 lakh annually).
3. Renunciation:
   • Selling rights entitlement attracts capital gains tax.
   • Gifted rights have no immediate tax but may impact the recipient later.
4. Dividend Income: Taxed at the shareholder's applicable slab rate.

You may consult a tax professional or review the latest tax laws for specific advice.